COPERNICUS Tolerability Data Closes Safety Gap But Leaves OS and Comparative Efficacy Questions Open

COPERNICUS Study Shows Low Treatment-Related Events for RYBREVANT FASPRO Plus LAZCLUZE

Johnson & Johnson announced new results from the Phase 2b COPERNICUS study at WCLC 2026, evaluating subcutaneous RYBREVANT FASPRO plus LAZCLUZE with prophylactic strategies for previously untreated advanced non-small cell lung cancer (NSCLC) with common EGFR mutations. The study, designed to reflect real-world clinical practice, showed consistently low rates of key treatment-related events, including rash (25%), administration-related reactions (3%), and venous thromboembolism (3%). Fewer than 1% of patients discontinued treatment due to these events at one year, indicating an improved treatment experience compared to previous intravenous regimens. These findings reinforce the regimen's potential as a first-line treatment, building on the survival benefits previously demonstrated in the MARIPOSA study.

• The COPERNICUS study demonstrated significantly lower rates of common treatment-related adverse events with subcutaneous RYBREVANT FASPRO plus LAZCLUZE compared to the intravenous formulation in the MARIPOSA study. Specifically, rash was reported in 25% of patients (vs. 55% in MARIPOSA), administration-related reactions in 3% (vs. 55%), and venous thromboembolism in 3% (vs. 23%). This improved safety profile, coupled with prophylactic strategies, led to a low treatment discontinuation rate of less than 1% due to these events at one year.
• COPERNICUS is a Phase 2b, single-arm study enrolling 214 U.S. patients with EGFR-mutated advanced NSCLC, designed to mirror everyday clinical care. It included a racially and ethnically diverse population across academic and community sites, with a median follow-up of 8.3 months. The study incorporated prophylactic strategies, such as oral anticoagulation to reduce blood clots and an enhanced skin care regimen to manage skin-related side effects, aiming to optimize the patient treatment experience.
• These new COPERNICUS results build upon the established efficacy of RYBREVANT plus LAZCLUZE, which previously showed a statistically significant overall survival benefit (HR, 0.75; P=0.005) over osimertinib in the first-line setting in the Phase 3 MARIPOSA study. By demonstrating low rates of treatment-related events and high treatment adherence with subcutaneous, less frequent dosing and prophylactic strategies, the COPERNICUS data further strengthens the evidence for this regimen as a comprehensive first-line option that extends survival while significantly improving the patient's treatment journey.

Addressing Treatment Burden in EGFR-Mutated NSCLC

Despite significant advances in targeted therapy for EGFR-mutated advanced NSCLC, the treatment landscape remains constrained by a set of persistent and interrelated challenges — from acquired resistance mechanisms to CNS disease management and long-term toxicity burden.

• Acquired resistance is inevitable and mechanistically diverse. All generations of EGFR-TKIs are ultimately limited by the development of acquired resistance. For third-generation agents such as osimertinib, resistance mechanisms include on-target EGFR modifications (tertiary C797S mutations, T790M loss), activation of bypass signaling pathways (MET, HER2, and AXL amplification), downstream alterations involving KRAS/BRAF and PI3K/AKT/mTOR cascades, and histologic transformations including SCLC transformation and epithelial-mesenchymal transition (EMT).

• Histological transformation to SCLC presents a particularly complex resistance scenario. SCLC transformation during osimertinib treatment is linked to concomitant alterations in EGFR, TP53, and RB1, as well as specific signal bypass mechanisms including EGFR and MET amplifications and activation of the PI3K/AKT/mTOR pathway. Detecting this transformation requires combining tissue and liquid biopsy profiling at multiple time points, and therapeutic options for EGFR-mutant SCLC remain limited to conventional genotoxic chemotherapy.

• CNS metastases and leptomeningeal disease remain a major clinical burden. Up to 40% of patients with EGFR mutation-positive NSCLC may develop CNS metastases throughout their disease course. First- and second-generation EGFR-TKIs have limited intracranial efficacy due to poor blood-brain barrier permeability. While third-generation TKIs such as osimertinib demonstrate meaningful intracranial activity — with a cORR of 62.5% (95% CI, 38.3–82.6%) and median cPFS of 13.0 months (95% CI, 7.21–18.8) in T790M-positive patients — leptomeningeal metastases continue to represent a particularly challenging subset, and the optimal integration of systemic therapy with local modalities such as stereotactic radiosurgery remains under investigation.

• Differential outcomes by EGFR mutation subtype complicate treatment optimization. Clinical outcomes vary by mutation type. In the osimertinib versus first-generation TKI comparison for leptomeningeal metastases, LM-PFS for patients with exon 19 deletion was significantly longer in the osimertinib group (32.7 months versus 13.4 months, P = 0.013), whereas outcomes for patients with L858R mutation in exon 21 did not differ significantly between treatment groups. This heterogeneity necessitates mutation subtype-stratified treatment planning.

• Long-term toxicity management is an ongoing concern across TKI generations. A pooled analysis of 21 trials (n = 1,468) found that grade ≥3 rash and diarrhea were significantly more frequent with afatinib than with erlotinib or gefitinib, while gefitinib was associated with a significantly higher frequency of grade ≥3 hepatotoxicity compared with erlotinib or afatinib. The overall frequency of adverse events leading to treatment withdrawal was 6.1% (83 of 1,354 evaluable patients), with withdrawal occurring significantly more often with afatinib or gefitinib than with erlotinib. Newer generation TKIs introduce distinct CNS and metabolic adverse event profiles that require careful management given the prolonged treatment durations involved.

COPERNICUS Reveals Improved Safety Profile for Subcutaneous RYBREVANT FASPRO

Amivantamab, a bispecific antibody targeting EGFR and MET, carries a well-characterised and clinically significant adverse event burden across its studied indications. Cutaneous toxicities are the most prevalent class of treatment-related effects: across 380 patients in the CHRYSALIS study, 296 (78%) experienced treatment-related rash and/or paronychia, with paronychia occurring in 43%, rash in 36%, dermatitis acneiform in 35%, and scalp rash in 17%. Real-world pharmacovigilance data from the FDA Adverse Event Reporting System (FAERS) corroborate this profile, identifying rash, paronychia, and acneiform dermatitis among the most frequently reported adverse events, alongside dyspnea, pneumonitis, pulmonary embolism, thrombocytopenia, nausea, deep vein thrombosis, febrile neutropenia, peripheral edema, hypokalemia, and neutropenia. Notably, 51.74% of all adverse events in the FAERS analysis occurred within the first month of treatment initiation. Vascular toxicity represents a distinct safety signal: a FAERS-based cardiovascular pharmacovigilance study identified four positive signal categories — venous thrombotic diseases, abnormal blood pressure, arrhythmia, and pericardial effusion — with a median time to onset of 33 days and a mortality rate of 16.3% across all cardiovascular adverse events; mortality rates for Major Adverse Cardiovascular Events reached up to 60%.

Infusion-related reactions (IRRs) are another defining feature of amivantamab's tolerability profile. In CHRYSALIS, IRRs were reported in 256 of 380 patients (67%), with most being grade 1 or 2; grade 3 and grade 4 IRRs occurred in 7 and 1 patients, respectively. The majority (90%) occurred on Cycle 1 Day 1, with a median time to first IRR onset of 60 minutes. A post hoc analysis confirmed that 98% of 273 IRRs occurred on Cycle 1 Day 1 or Day 2, with median onset and time to resolution both at 60 minutes, and infusion duration decreasing from a median of 4.70 hours (1,050 mg) and 5.08 hours (1,400 mg) at Cycle 1 Day 1 to 2.20 and 2.25 hours, respectively, by Cycle 1 Day 22. Only 4 patients (1%) discontinued treatment due to IRR. In the French real-world Amexon 20 GFPC study, grade ≥ 3 adverse events occurred in 11 patients (28.2%), driven mainly by skin toxicity (12.8%) and infusion reactions (5.1%), leading to dose reductions in 17.9% and permanent discontinuation in 10.3% of patients.

Lazertinib, a third-generation EGFR tyrosine kinase inhibitor, demonstrated a distinct but manageable tolerability profile in a real-world cohort of 103 patients with acquired EGFR T790M-mutated NSCLC. Peripheral sensory-motor adverse events were the most clinically impactful, occurring in 65 patients (63.1%), including paresthesia in 58 and muscle cramping in 24. These events led to dose reduction in 17 patients (16.5%) and permanent discontinuation in 5 (4.9%). Overall, dose adjustment was required in 39 patients (37.9%), including 10 (9.7%) with permanent discontinuation. Importantly, there was no treatment-related mortality, and no difference in progression-free survival was observed between patients with and without dose adjustment (P=0.40), indicating that dose modification did not impair clinical efficacy. In the context of first-line combination regimens, the MARIPOSA trial data — reviewed in the context of treatment intensification strategies — indicate that amivantamab-lazertinib is associated with increased rates of grade ≥ 3 adverse events and treatment discontinuation compared to osimertinib monotherapy, raising tolerability considerations particularly relevant for frailer patients in real-world settings.

Advancing First-Line Treatment for EGFR-Mutated NSCLC

The approval of osimertinib as a first-line standard of care for EGFR-mutated advanced NSCLC established a high benchmark, with the FLAURA trial reporting a median progression-free survival (PFS) of 18.9 months. Real-world evidence from a retrospective analysis of 365 Bulgarian patients treated with first-line osimertinib corroborated these findings, with a real-world median PFS of 19.1 months and an objective response rate (ORR) of 26% versus 14% in FLAURA, suggesting that outcomes in routine clinical practice closely align with — and may modestly exceed — those observed in the controlled trial setting.

Subsequent phase 3 trials have sought to improve upon osimertinib monotherapy through combination strategies. The FLAURA2 trial evaluated osimertinib plus chemotherapy, and the MARIPOSA trial assessed amivantamab plus lazertinib, both demonstrating survival benefits over osimertinib monotherapy. An exploratory analysis from MARIPOSA also provided the first randomized, double-blind comparison of two third-generation EGFR-TKIs — lazertinib and osimertinib — at a median follow-up of 22.0 months, finding comparable efficacy: median PFS of 18.5 versus 16.6 months (HR, 0.98; 95% CI, 0.79–1.22; P=0.86), ORR of 83% versus 85%, and median overall survival not reached in either arm (HR, 1.00; 95% CI, 0.73–1.38). Lazertinib was associated with lower rates of QT interval prolongation versus osimertinib, with adverse events in both arms predominantly grade 1–2.

The clinical gains from combination regimens must, however, be weighed against increased healthcare burden and cost. A time toxicity analysis of FLAURA, FLAURA2, and MARIPOSA estimated total healthcare contact days of 1.03, 3.635, and 6.425 days, respectively, highlighting a significant escalation in burden with each successive combination strategy. From a health economics perspective, a cost-effectiveness analysis found that, compared with osimertinib monotherapy, the incremental cost-effectiveness ratios (ICERs) for osimertinib plus chemotherapy were $551,944/QALY (US) and $37,965/QALY (China), while amivantamab plus lazertinib yielded ICERs of $2,186,499/QALY (US) and $291,478/QALY (China). Probabilistic sensitivity analysis indicated that osimertinib monotherapy was cost-effective in 100% of US simulations at a $150,000/QALY threshold, and osimertinib plus chemotherapy had a 74.10% probability of cost-effectiveness in China at the local threshold — underscoring that the optimal first-line regimen remains context-dependent, shaped by both clinical and economic considerations.

Subcutaneous Amivantamab-Lazertinib: A New Era for First-Line EGFRm NSCLC

The latest data from the COPERNICUS study heralds a significant step forward in the management of previously untreated advanced EGFR-mutated non-small cell lung cancer (NSCLC). The introduction of a subcutaneous (SC) formulation of RYBREVANT FASPRO (amivantamab) combined with LAZCLUZE (lazertinib) addresses a critical need for improved patient experience in a chronic disease setting. Historically, intravenous (IV) amivantamab was associated with a high burden of infusion-related reactions (IRRs) and lengthy administration times, which could impact patient adherence and overall quality of life.

The COPERNICUS results demonstrate a remarkable reduction in key treatment-related events, including rash (25%), IRRs (3%), and venous thromboembolism (3%), with very few patients discontinuing treatment due to these issues. This enhanced tolerability, coupled with the significantly shorter administration time of the SC formulation, transforms the treatment landscape. Patients can now potentially receive a highly effective therapy with less disruption to their daily lives, fostering better adherence and sustained treatment benefits.

This improved safety and convenience profile builds upon the robust overall survival benefits previously observed with the amivantamab-lazertinib combination in the MARIPOSA study. The regimen has also shown a favorable impact on resistance mechanisms, reducing common acquired alterations like MET amplifications and secondary EGFR mutations compared to osimertinib, suggesting a shift in the underlying biology of the disease.

However, strategic considerations remain. While IRRs are significantly reduced, other adverse events like rash and venous thromboembolism still require careful monitoring and proactive management. Furthermore, in the competitive first-line landscape, the regimen's efficacy in specific subgroups, such as patients with central nervous system metastases, will continue to be a point of comparison against established options like osimertinib-chemotherapy, which has shown a progression-free survival advantage in these populations. The long-term implications of 'unknown' resistance mechanisms also warrant ongoing investigation to optimize subsequent treatment strategies. Despite these considerations, the subcutaneous amivantamab-lazertinib combination is poised to become a compelling and patient-preferred first-line option, offering a powerful blend of efficacy and significantly improved tolerability.